Pancreatic Cancer Research

Clinical trialPhase 1Terminated

A Study of BND-35 in Participants With Advanced Solid Tumors

A Phase 1, Dose Escalation and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of BND-35 Administered Alone and in Combination With Nivolumab or With Cetuximab in Patients With Advanced Solid Tumors

Outcome
Stopped earlyStudy terminated due to strategic considerations (Business decision)
Phase
Phase 1
Status
Terminated
Study type
Interventional
Start
2 June 2024
Ended
29 April 2026
Enrollment
12 participants
Sites
5
Primary outcomes
Part 1: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); Part 1: Proportion of patients who discontinued study treatment due to TEAEs; Part 1: Incidence of TEAEs dose limiting toxicities (DLT); Part 2: Objective Response Rate (ORR) per RECIST v1.1; Part 2: Incidence of TEAEs and SAEs
Sponsor type
Industry
Results posted
No
Last update
18 June 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is an open-label, multicenter, dose escalation and dose optimization study designed to evaluate safety, tolerability and preliminary anti-tumor activity of BND-35 administered alone and in combination with nivolumab or with cetuximab. The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy. The study will be comprised of two parts - a dose escalation phase (Part 1) and a dose optimization (Part 2). Part 1 is comprised of three sub-parts: BND-35 administered alone (Sub-Part 1A), BND-35 administered in combination with nivolumab (Sub-Part 1B), and BND-35 administered in combination with cetuximab (Sub-Part 1C). Part 2 is composed of two sub-parts: a dose optimization part where up to two doses of BND-35 per indication are administered in combination with nivolumab or with cetuximab.

Detailed description public domain (ClinicalTrials.gov)

Estimated Study Duration: Dose Escalation (Part 1): Approximately 34 months. Dose Optimization/Expansion (Part 2): Approximately 24 months.